Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19

COVID-19 emergency use authorizations and approvals for vaccines were achieved in record time. However, there remains a need to develop additional safe, effective, easy-to-produce, and inexpensive prevention to reduce the risk of acquiring SARS-CoV-2 infection. This need is due to difficulties in va...

Descripción completa

Detalles Bibliográficos
Autores principales: Frumkin, Lyn R., Lucas, Michaela, Scribner, Curtis L., Ortega-Heinly, Nastassja, Rogers, Jayden, Yin, Gang, Hallam, Trevor J., Yam, Alice, Bedard, Kristin, Begley, Rebecca, Cohen, Courtney A., Badger, Catherine V., Abbasi, Shawn A., Dye, John M., McMillan, Brian, Wallach, Michael, Bricker, Traci L., Joshi, Astha, Boon, Adrianus C. M., Pokhrel, Suman, Kraemer, Benjamin R., Lee, Lucia, Kargotich, Stephen, Agochiya, Mahima, John, Tom St., Mochly-Rosen, Daria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199392/
https://www.ncbi.nlm.nih.gov/pubmed/35720389
http://dx.doi.org/10.3389/fimmu.2022.899617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199392/
https://www.ncbi.nlm.nih.gov/pubmed/35720389
http://dx.doi.org/10.3389/fimmu.2022.899617

Ejemplares similares